BOULDER, Colo.--Xenometrix, a biotechnology firm here announced last month that it granted licenses to both Incyte and SmithKline Beecham for its gene expression profiling technology. The nonexclusive license for the technology, for which Xenometrix received a US patent in September, covers the collection of gene expression profiles utilizing all methods, including high-density microarrays. Gene Logic, Rosetta Inpharmatics, Cerep, Affymetrix, and Aurora Biosciences are among other companies that have licensed the Xenometrix technology. SmithKline is Xenometrix's first large pharmaceutical customer.
Incyte, SmithKline License Xenometrix's Patented Gene Expression Profiling
Feb 25, 1999